Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said ...

Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...

Pfizer cuts 2026 revenue forecast as COVID sales fade and patents expire. The firm bets on a monthly obesity drug and ...

Pharmaceutical company Pfizer said Friday it was blocking use of its drugs in lethal injections, which means all federally-approved drugmakers whose medications could be used for executions have now ...